Precision Biosciences (DTIL) Equity Ratio (2018 - 2025)
Precision Biosciences (DTIL) has disclosed Equity Ratio for 8 consecutive years, with 0.18 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio fell 57.97% to 0.18 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.18, a 57.97% decrease, with the full-year FY2024 number at 0.41, up 250.28% from a year prior.
- Equity Ratio was 0.18 for Q3 2025 at Precision Biosciences, down from 0.31 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.45 in Q2 2024 to a low of 0.12 in Q4 2023.
- A 5-year average of 0.31 and a median of 0.31 in 2025 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: crashed 58.24% in 2021, then surged 250.28% in 2024.
- Precision Biosciences' Equity Ratio stood at 0.43 in 2021, then tumbled by 41.14% to 0.25 in 2022, then plummeted by 53.48% to 0.12 in 2023, then soared by 250.28% to 0.41 in 2024, then tumbled by 56.98% to 0.18 in 2025.
- Per Business Quant, the three most recent readings for DTIL's Equity Ratio are 0.18 (Q3 2025), 0.31 (Q2 2025), and 0.4 (Q1 2025).